Skip to main content
Retour
Watch Compare

Cordyceps Sunshine Biotech Holdings Co., Ltd.

Qualité des données : 100%
RAJAF
OTC Manufacturing Chemicals
9,18 €
0,00 € (0,00%)
Cap. Boursière: 1,02 B
Prix
9,18 €
Cap. Boursière
1,02 B
Fourchette du Jour
3,01 € — 3,01 €
Fourchette 52 Semaines
3,01 € — 10,56 €
Volume
154
Ouverture 3,01 €
Moyenne 50J / 200J
9,18 €
0,00% above
Moyenne 50J / 200J
9,16 €
0,20% above

Quick Summary

Points Clés

Net margin of 93,35% shows strong profitability
Generating 117 315,0 in free cash flow
P/E of 1238,17 — premium valuation
ROIC of 345,70% — excellent capital efficiency

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-29,59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC345,70%
Net Margin93,35%
Op. Margin25,54%

Sécurité

Debt / Equity
N/A
Current Ratio0,04
Interest Coverage8,49

Valorisation

PE (TTM)
1238,17
Au-dessus de la moyenne du secteur (-1,47)
P/B RatioN/A
EV/EBITDA3615,44
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E 1238,2 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % 93,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -29,59% Revenue Growth (3Y) 40,23%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 882 533,0 Net Income (TTM) 823 860,0
ROE N/A ROA 20,48%
Gross Margin 86,84% Operating Margin 25,54%
Net Margin 93,35% Free Cash Flow (TTM) 117 315,0
ROIC 345,70% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,04
Interest Coverage 8,49 Asset Turnover 0,22
Working Capital -1,41 M Tangible Book Value -182 939
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 1238,17 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1155,86
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 3615,44 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 0,01%
Market Cap 1,02 B Enterprise Value 1,02 B
Per Share
EPS (Diluted TTM) 0,01 Revenue / Share 0,01
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 23,50% FCF Conversion 14,24%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2023 FY2024 FY2022
Revenue 882 533,0 1,25 M 448 785,0
Net Income 823 860,0 -226 258,0 -720 093,0
EPS (Diluted) 0,01 0,00 -0,01
Gross Profit 766 387,0 533 760,0 -66 672,0
Operating Income 225 384,0 -183 913,0 -642 702,0
EBITDA — — —
R&D Expenses 118 444,0 118 444,0 118 444,0
SG&A Expenses — — —
D&A 56 757,0 — 168 899,0
Interest Expense 26 535,0 — 71 772,0
Income Tax -42 221,0 34 957,0 792,0

Balance Sheet

Annual, most recent first
Metric FY2023 FY2024 FY2022
Total Assets 3,42 M 4,62 M 2,10 M
Total Liabilities 3,50 M 5,00 M 3,06 M
Shareholders' Equity -78 731,0 -375 543,0 -951 334,0
Total Debt 431 079,0 431 079,0 —
Cash & Equivalents 15 278,0 37 284,0 16 100,0
Current Assets 330 973,0 601 602,0 501 552,0
Current Liabilities 2,93 M 4,99 M 2,94 M